Cancer Centers Support Grants

Active

Assistance listing
93.397
Agency
Grant awards
1,707 $18,466,139,389 in federal obligations

Program facts

Also known as
Cancer Centers
Assistance types
  • Project Grant
  • Cooperative Agreement
  • Block Grant
Treasury account
  • 75-0849-0-1-550
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The National Institutes of Health National Cancer Institute funds Cancer Centers Support Grants (CCSG, CFDA 93.397) to provide organizational infrastructure and resources enabling interdisciplinary cancer research spanning basic laboratory, clinical, and population science. The program awarded its most recent grant on August 18, 2026, and has distributed $18.47 billion in federal funding across 1,707 awards dating back to 1976.

The program funds salaries for scientific leadership, shared research resources, administrative costs, planning and evaluation activities, and developmental funds supporting new investigator recruitment and feasibility studies within cancer centers. Recent awards exemplify this scope: the Emory Lung Cancer SPORE received $2.19 million to investigate immunotherapy efficacy and artificial intelligence approaches for stage III non-small cell lung cancer; the Dana-Farber/Harvard leukemia SPORE received $2.43 million to examine resistance mechanisms to menin inhibitors and test combination therapies; and the University of Florida Health Cancer Center received $15.3 million as a new basic cancer center supporting transdisciplinary programs in genetics, epigenetics, metabolism, and cancer control across a 27-county catchment area serving medically underserved populations.

Awards are predominantly Project Grants (81%), with smaller shares of Cooperative Agreements (17%) and Block Grants (2%). The National Cancer Institute dominates funding, accounting for 374 awards valued at $15.5 billion—84% of total federal dollars obligated. The broader NIH contributed 1,293 awards totaling $2.52 billion. Award magnitude varies widely, ranging from approximately $1.19 million to $15.3 million, with recent awards clustering between $2 million and $10 million.

Activity remains robust: 2025 produced 9 awards and 2026 has yielded 3 awards to date, though the 2024 pace (6 awards) signals potential fluctuation. Annual volume peaked in 2023 at 36 awards but has moderated since.

Applicants must be nonprofit institutions within the United States with a peer-reviewed cancer research base of at least $4 million in direct costs. Recent opportunities emphasize cancer health equity and disparities research, including the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) program (PAR-23-308, due February 21, 2025) supporting partnerships between cancer centers and institutions serving underserved populations. Broader career development and investigator-focused mechanisms also remain active, including the NCI Outstanding Investigator Award (R35, multiple PAR cycles) and the Cancer Center Support Grants renewal cycle (PAR-25-444, due September 25, 2028), which permits Clinical Trial Optional approaches.

Objective and description

Objective

To provide an organizational focus and stimulus for the highest quality cancer research that effectively promotes interdisciplinary cancer research aimed toward the ultimate goal of reducing cancer incidence, mortality and morbidity. The Cancer Cente

Description

To provide an organizational focus and stimulus for the highest quality cancer research that effectively promotes interdisciplinary cancer research aimed toward the ultimate goal of reducing cancer incidence, mortality and morbidity. The Cancer Center Support Grant (CCSG) provides the resources and infrastructure to facilitate the coordination of interdisciplinary programs across a broad spectrum of research from basic laboratory research to clinical investigation to population science. The CCSG supports salaries for scientific leadership of the Center, shared resources for funded center investigators, certain administrative costs, planning and evaluation, and developmental funds for new recruitments and feasibility studies.

Eligibility

Applicant eligibility

Any nonprofit institution within the United States with a peer-reviewed cancer research base of 4.0 million dollars in direct costs may apply for a Cancer Center Support Grant.

Beneficiary eligibility

University, college, public agency or research institution in the U.S.

Uses of assistance

In general, CCSGs do not support research projects directly but are used to enhance the ongoing cancer research and to strengthen the existing research base according to the "Policies and Guidelines Relating to the Cancer Center Support Grant."

Length and time phasing of assistance

Up to 5 years of support may be requested. Grants may be awarded up to 5 years based on competitive peer review.

How to apply

Criteria for selecting proposals

The major elements in evaluating applications include the following: (1) An adequate base of established programs of high quality in laboratory and clinical cancer research; (2) research activity in a variety of disciplines, and evidence of high degree of interdisciplinary coordination, interaction and cooperation among center members; (3) appropriate and adequate organization and facilities for the conduct and evaluation of center activities; (4) a qualified director with adequate authority; and (5) an adequate commitment of the parent institution or institutions to the cancer center. The center should be recognized as a major element within the organizational structure.

Award procedure

Grant applications are evaluated by scientific authorities for scientific and technical merit. Applications must also be reviewed by the National Cancer Advisory Board. All competitive applications compete for available funds on the basis of scientific and technical merit, program relevance, and program balance, consistent with NCI and NIH priorities and strategic plans. Initial award provides funds for the first budget period (usually 12 months) and Notice of Grant Award (Form PHS 1533-2) indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any.

Time to approval or disapproval

Core Grants: Approximately 10 months.

Renewals

Same procedure as new applications.

Appeals

A principal investigator may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-064.html and NIH Policy Manual Release date: February 7, 2012 http://oma.od.nih.gov/manualchapters/grants/54513/index.html).

Grant opportunities

Opportunity Status Posted Applications due
Investigator-Focused Award (Parent R35) PAR-28-037 Forecasted —
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) PAR-27-089 Forecasted —
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) PAR-27-088 Forecasted —
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) PAR-26-149 Forecasted —
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) PA-26-002 Open
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) PAR-25-444 Open
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional) PAR-25-324 Open
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32) PA-25-168 Open
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) PAR-24-274 Closed
Successor-in-Interest (Type 6 Parent Clinical Trial Optional) PA-24-253 Open
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) PA-24-254 Open
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional) PAR-23-308 Closed
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-23-243 Closed
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-23-242 Closed
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional) PAR-22-249 Closed
NCI Outstanding Investigator Award (R35 Clinical Trial Optional) RFA-CA-22-045 Closed
Point-of-Care Technologies Research Network: Technology Research and Development Centers (TRDC) (U54 Clinical Trial Optional) PAR-22-203 Closed
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-22-187 Closed
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-22-188 Closed
Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional) RFA-CA-22-027 Closed
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) PAR-22-114 Closed
Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24 Clinical Trial Not Allowed) RFA-CA-22-014 Closed
Stimulating Access to Research in Residency (StARR) (R38) RFA-HL-23-006 Closed
Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed) PAR-22-073 Closed
NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) PAR-21-333 Closed
Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24 Clinical Trial Not Allowed) RFA-CA-21-058 Closed
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) PAR-21-306 Closed
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-21-286 Closed
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-21-285 Closed
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) PA-21-268 Closed
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) PAR-21-138 Closed
Notice of Intent to Publish: Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium Coordinating and Data Management Center (PSRC CDMC) (U24 - Clinical Trial Not Allowed) NOT-CA-21-076 Past —
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-20-288 Closed
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-20-287 Closed
NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) PAR-20-278 Closed
NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) PAR-20-052 Closed
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) PAR-20-043 Closed
Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38) (Clinical Trial Not Allowed) RFA-HL-20-006 Closed
NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) PAR-19-349 Closed
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-19-290 Closed
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-19-291 Closed
U.S.-China Program for Biomedical Collaborative Research (R01 Clinical Trial Optional) RFA-CA-19-009 Closed
Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network (Admin Suppl Clinical Trial Not Allowed) PA-19-035 Closed
Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial Not Allowed) PA-19-029 Closed
Administrative Supplements to Cancer Center Support Grants to Strengthen the Research, Training, and Outreach Capacity of the Geographic Management of Cancer Health Disparities Program (Admin Suppl - Clinical Trial Not Allowed) PA-18-934 Closed
Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network (Admin Suppl - Clinical Trial Not Allowed) PAR-18-931 Closed
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-18-887 Closed
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-18-888 Closed
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) PA-18-842 Closed
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional) PAR-18-767 Closed
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Grant awards

Award Recipient Federal obligations Awarded
Emory university lung cancer spore - overall summary/abstract lung cancer is the leading cause of cancer-related… P50CA302567 Emory University $2,194,434
Spore in leukemia - overall summary the overall goal of this spore in leukemia is to improve understanding of the… P50CA298970 Dana-Farber Cancer Institute, Inc. $2,433,959
Basic cancer center - cancer center at illinois - technological advances over the past few decades have transformed our… P30CA275774 University Of Illinois $3,380,540
Reducing ethnic disparities in acute leukemia (redial) U54CA302464 Baylor College Of Medicine $7,482,330
Personalized outreach and multifaceted interventions for screening enhancement (promise) for anal and cervical cancer… U54CA302465 University Of Miami $4,672,458
UT southwestern liver cancer spore - the UT southwestern (utsw) liver cancer spore assembles a multidisciplinary team… P50CA295495 The University Of Texas Southwestern Medical Center $10,053,200
Cancer health disparities spore in endometrial cancer - endometrial cancer (EC) is increasing in frequency and… U54CA302426 University Of North Carolina At Chapel Hill $4,512,764
Neuroendocrine tumor specialized programs of research excellence (spore) in human cancer - overall P50CA302572 The University Of Iowa $4,332,345
Lymphoma outcomes spore - across lymphoma subtypes, african american (AA) and hispanic patients experience marked… U54CA302435 The Univeristy Of Texas M.d. Anderson Cancer Center $2,561,113
MD anderson sarcoma spore - the overarching goal of the university of texas MD anderson cancer center (MD anderson)… P50CA302482 The Univeristy Of Texas M.d. Anderson Cancer Center $1,824,620

Latest 10 of 1,707 listed here. See the rest on GovTribe.

Top recipients by federal obligations

10 of 180 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2026 $550,730,128
FY2025 $1,679,353,653
FY2024 $1,936,789,342
FY2023 $2,320,631,584
FY2022 $1,976,083,462
FY2021 $1,058,455,569
FY2020 $567,943,534
FY2019 $538,836,383
FY2018 $537,133,743
FY2017 $512,811,634
FY2016 $520,014,368
FY2015 $476,774,126
FY2014 $498,637,273
FY2013 $479,818,574
FY2012 $519,312,324
FY2011 $527,424,393
FY2010 $534,612,025
FY2009 $458,161,685
FY2008 $198,668,367
FY2007 $282,170,627
FY2006 $346,100,270
FY2005 $395,590,503
FY2004 $376,784,213
FY2003 $299,330,805
FY2002 $263,891,747
FY2001 $102,914,321
Show all 26

Quick answers

What is Assistance Listing 93.397?

Assistance Listing 93.397 is Cancer Centers Support Grants, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for Cancer Centers Support Grants?

Its CFDA number is 93.397: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.397 awarded?

1,707 grant awards under 93.397 have obligated $18,466,139,389 in federal funds to 180 recipients.

Who receives the most funding from 93.397?

The recipients obligated the most under Cancer Centers Support Grants are Dana-Farber Cancer Institute, Inc. ($955,897,350), Sloan-Kettering Institute For Cancer Research ($794,428,192) and The Univeristy Of Texas M.d. Anderson Cancer Center ($704,386,146).

How much did 93.397 obligate in fiscal year 2025?

Grants under 93.397 obligated $1,679,353,653 in federal funds in fiscal year 2025.

Are there open grant opportunities under 93.397?

10 of the latest 50 opportunities under 93.397 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program